Navigation Links
Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Date:7/25/2008

etabolic biomarkers as well as evaluations of mood and cognition were also found to be stable in subjects receiving all levels of the drug or placebo during the trial. These positive Study MSI-1436C-103 results are expected to enable further study to fully validate proof-of-concept of MSI-1436 in an ascending multiple-dose clinical trial planned to begin later this year.

Data were also presented from preclinical studies which demonstrated that systemically administered MSI-1436 crossed the blood-brain barrier and functionally inhibited PTP1B in the hypothalamus. In this study, rats were administered a single dose of MSI-1436 one day prior to receiving insulin; 30 minutes post-insulin, hypothalami were harvested to determine the level of phosphorylated-insulin receptor beta (IR-beta), a target of PTP1B. Previous studies had shown that MSI-1436 is a reversible, noncompetitive inhibitor of PTP1B with the ability to cross the blood brain barrier. In the hypothalamus, MSI-1436 enhanced the insulin-induced phosphorylative state of the insulin receptor, which confirms the functionality of MSI-1436 in this key regulatory center of the brain. The combination of central and peripheral inhibition makes MSI-1436 a promising therapeutic candidate for both obesity and type 2 diabetes.

"The data reported today support continuing confidence in our ability to administer trodusquemine to a wide range of obese and type 2 diabetic patients," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "MSI-1436 is the only reversible, noncompetitive inhibitor of PTP1B in clinical stage development that functionally inhibits PTP1B in the periphery and in the hypothalamus. This dual mechanism of action, with the demonstrated ability to cross the blood-brain barrier, makes MSI-1436 an exciting therapeutic for further clinical study."

About Trodusquemine (MSI-1436)

Trodusquemine is a centrally and peripherally-acting appetite suppressant and the firs
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
11. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... April 20, 2015  Fewer blockbusters drugs are expected ... of opportunities for generic companies in Asia ... are looking beyond the patent cliff to focus on ... Certain established generic manufacturers are restructuring their business models ... molecules, although the impact of these efforts will take ...
(Date:4/20/2015)... PORTLAND, Ore. , April 20, 2015 /PRNewswire/ ... the National Academy of Sciences (PNAS) demonstrates ... & Science University,s Casey Eye Institute ... causes of blindness. Optical coherence tomography (OCT) angiography ... management of these diseases. OHSU researchers ...
(Date:4/20/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ... the Phase 1 study of MM-302, a novel ... The results were presented today by Patricia LoRusso, ... at the 2015 American Association for Cancer Research ... Data described the safety and promising ...
Breaking Medicine Technology:Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 2Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 3Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 4Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 5Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5
... Life Pharmaceuticals, soon to be changed from Hybrid Fuels, ... that it is in development of an online pharmacy ... the Company to sell and service internationally while building ... part of the online pharmacy, the Company will provide ...
... CARDIFF, Calif., March 7, 2012 NeuroPerspective ... area, has released its March issue, which reviews the field ... "There are those that claim that ADHD is a fabrication, ... psychotropic web in the name of corporate profits. Even well-regarded ...
Cached Medicine Technology:HRID Launches Plan to Expand Into World-Wide Market 2ADHD Therapeutics Reviewed by NeuroPerspective 2ADHD Therapeutics Reviewed by NeuroPerspective 3
(Date:4/21/2015)... (PRWEB) April 21, 2015 Invictus ... a prestigious Illinois university for a second innovative ... (NICUs) more conducive to newborn infants’ cognitive development. ... three NICU problems we have identified through extensive ... professionals,” said George Hutchinson, Invictus Medical’s Chief Technology ...
(Date:4/21/2015)... San Diego, CA (PRWEB) April 21, 2015 ... owner of SunGrubbies.com. “Doesn’t every mother want to look younger ... sun protection is the first line of defense. ... spots that are the evidence of too much time spent ... not the only reason to cover up. The dangers ...
(Date:4/20/2015)... 20, 2015 Heritage Woods of Centralia, ... Open House and Dine-and-Dash Spaghetti Dinner from 4 p.m. ... which is located in Centralia, Illinois, houses senior living ... low-income adults 55 and older. , Guests are invited ... supportive living options for seniors. After the tours, they ...
(Date:4/20/2015)... 2015 Using Quality by Design to ... and Improve Compliance , **FDAnews Webinar**, May 7, 2015 ... , The life sciences industries are going through ... more with less. Mergers, acquisitions, the patent cliff ... ways to speed up production while still maintaining quality ...
(Date:4/20/2015)... Reality show stars, food, fashion and fun ... annual Michigan International Women’s Show, April 30 - May ... lots to see and do from enjoying a makeover ... gifts,” said Beth Anderson, executive show manager of Southern ... appearances from Randy Fenoli of ‘Say Yes to the ...
Breaking Medicine News(10 mins):Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2Health News:Sun’s the Word this Mother’s Day Say’s SunGrubbies.com, a Leading Retailer of Sun Protection Products 2Health News:Heritage Woods of Centralia Senior Living Community to Host Open House and Spaghetti Dinner 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 3Health News:Perfect Girls Day Out at Michigan International Women’s Show Opening Thursday, April 30 in Novi Presented by Southern Shows 2Health News:Perfect Girls Day Out at Michigan International Women’s Show Opening Thursday, April 30 in Novi Presented by Southern Shows 3
... Wound Management,Technologies, Inc., (OTC Bulletin Board: WNDM), announced ... and for 2009. "The company,has been focused on bringing ... 3 quarters of the year to position CellerateRx(TM) as ... We have been working,with several major medical groups, physicians ...
... There is little doubt that Playboy founder Hugh Hefner ... the past half century. From his highly publicized lifestyle ... Hefner has played a leading role in reshaping America,s ... Steven Watts, professor of history in the College of ...
... Sept. 11 A US House Government,Oversight subcommittee ... a mandatory requirement, to reduce mercury emissions. The,Mercury ... at two,congressional hearings over the past several months ... Subcommittee report found that the best way to ...
... Breast Cancer Coalition and celebrate fifteen,years of Education, ... The Pennsylvania,Breast Cancer Coalition (PBCC) Annual Conference ... the Harrisburg Hilton & Towers from 7 a.m. ... of education, advocacy, and research., Pat Halpin-Murphy, ...
... 2008, CHENGDU, China, Sept. 11 /Xinhua-PRNewswire-FirstCall/ ... TYNP), a manufacturer and,supplier of modernized traditional ... announced that the Company has received approval ... (SFDA) to produce Laonian,Kechuan Tablets in the ...
... prominent international awards from the European Society of Cardiology ... treat conditions of the heart. , Professor John Martin, ... Medicine and British Heart Foundation Professor of Cardiovascular Science, ... other holder of this medal in the UK is ...
Cached Medicine News:Health News:Wound Management Technologies, Inc. Announces Strategic Plans for Revenue Growth for Year End and 2009 2Health News:Playboy founder embodies American Dream; changes American culture 2Health News:To Reduce Mercury Pollution, 'Dentists need a mandatory requirement,' According to US House Oversight Report; Mercury Group Concurs 2Health News:Pennsylvania Breast Cancer Coalition Hosts Annual Conference 2Health News:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets 2Health News:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets 3Health News:UCL academics awarded prestigious prizes for work on the heart 2
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
... System from KUBTEC is a dual capability system ... dimensional representation of the specimen under test. While ... X-ray images, the micro focus source also allows ... in standard 2D images. The 100 mm x ...
... The Duet Logic G|2 Provides Microsoft ... and reporting for clinics where logic, ... Medtronic diagnostic system is designed with ... physicians to combine different diagnostic tools ...
... experience in the field of Urodynamics, Albyn Medical ... Our new chair is manufactured from the highest ... studies can be improved considerably if the patient ... and this aspect was given a high priority ...
Medicine Products: